Click for quick access:

PROSTest

The NETest

NETest PPQ

Our Diagnostics and Your Patients

Liquid biopsy mRNA tests that characterize cancer with accuracy, sensitivity, and specificity

Delivering a cancer diagnosis to a patient is one of the most overwhelming tasks doctors are faced with. Initial patient reactions can be emotionally charged, marked by acute fear, doubt, sadness, or anxiety, all stemming from the uncertainty of the situation.

If your patient has been diagnosed with neuroendocrine cancer or prostate cancer, our molecular blood tests can remove some of the uncertainty from this diagnosis.

mRNA-based Molecular Cancer Test

Our diagnostic assesses a targeted gene profile of mRNA isolated from peripheral blood, enabling us to understand tumor disease activity*, recommend treatment, and then monitor recovery for NET, NEN, and prostate cancer patients in real-time. Quick and non-invasive, results from our liquid biopsy assays can be shared within 48 hours.

Expanding Usage Throughout the US

Our tests, which deliver higher levels of sensitivity, specificity, and accuracy than any other testing method available today, have been used over 10,000 times in medical centers throughout the United States. They help oncologists and patients manage and monitor treatment and quickly detect the recurrence of disease.

*Disease activity is defined as the calculated risk of highly active disease as measured by an algorithm based on gene expression data. Test results should be used in conjunction with standard clinical assessment.

Empirical Benefits

 mRNA Diagnostic Performance

Be it blood or saliva, our molecular cancer tests provide actionable disease diagnostics in real-time.

Accuracy

The National Cancer Institute, peer-reviewed research, and our decades of experience demonstrate mRNA is unsurpassed for testing accuracy.

Sensitivity

The Wren Laboratories  NETest has exhibited 98% sensitivity while the Wren PROSTest has demonstrated 95% sensitivity.

Specificity

The NETest has exhibited specificity levels  in excess of 95% while preliminary results for our new PROSTest indicate 90% specificity.

A liquid biopsy NET diagnostic to help doctors better understand and manage neuroendocrine cancer

The NETest

Commercially introduced in 2014, the NETest has gained widespread utilization among neuroendocrine cancer patients in cancer clinics and medical centers across the US. This blood-based diagnostic employs mRNA and our proprietary 51-gene expression assay to aid in diagnosis, treatment recommendations, and real-time progress monitoring.

Quick and non-invasive, results from our liquid biopsy can be shared within 48 hours after receipt of a blood sample. After analysis with our multianalyte algorithm suite, we produce a personalized risk score that will help oncologists:

Understand the disease state of the neuroendocrine tumor – is it indolent,  or aggressive?

Determine the success of surgery – was the entire NET removed? Is there residual disease? What are the chances of a recurrence?

Predict therapy response – provide understanding of how the tumor will likely respond to various therapies.

Treatment monitoring – determine whether the patient is responding to therapy or requires treatment.

Ordering a NETest

Use the button below to link to the Requisition Input form page. If you have any questions about sample preparation or the sample submission process, click the NETest Sample Process button.

Questions? Contact us via email or call (203) 208-3464

NETest PPQ

Companion Diagnostic to Predict Response to Peptide Receptor Radionuclide Therapy

The PRRT Predictive Quotient, or PPQ/PRRedicTor, is a companion diagnostic to the NETest developed to predict peptide receptor radionuclide therapy (PRRT) response in bronchopulmonary and gastroenteropancreatic neuroendocrine tumor patients. The test is based on an algorithm that combines normalized gene expression from 8 targeted genes (a subset of the NETest) and the histological grade of the NET.

PRRT in Practice

PPQ is an accurate (>96%) predictor of patient response to PRRT

PPQ Responders vs Non Responders

PPQ classifies patients as either a “Responder” who will respond to PRRT, experience disease stabilization and a longer time to progression (usually >18 months after the end of PRRT) or a “Non-responder”,  who will have a shorter time until the disease progresses (usually <12 months after the start of PRRT). Patients predicted as “Non-responder” may require additional therapies to stabilize their disease.

Research indicates that PPQ can forecast a patient’s response to PRRT therapy with 96% accuracy, as demonstrated in recent peer-reviewed research published in the April, 2023 Journal of Nuclear Medicine.

NETest Fast Facts

Four reasons to consider the NETest for your Neuroendocrine Tumor patients

Has been the subject of over 60 academic papers, peer-reviewed studies, and articles in medical journals.

Delivers higher levels of sensitivity, specificity, and accuracy than any other testing method available today.

Helps oncologists and patients manage and monitor treatment and quickly detect disease recurrence.

The NETest has been commercially available for almost 10 years and has been utilized over 10,000 times.

Frequently Asked Questions

Answers to frequent patient questions about the NETest

Our Frequently Asked Questions section provides answers to the most common questions. If your patient’s question isn’t answered, please contact us. We’ll answer it and then add it to the FAQ.

Introducing a less invasive, more accurate blood-based Prostate Cancer Diagnostic.

PROSTest

We are developing a multi-mRNA liquid biopsy biomarker assay that can help detect and define the molecular pathology of a patient’s prostate cancer with a simple blood test. 

Currently an “Investigational Use Only” test, our soon-to-be-released PROSTest is a blood-based, non-invasive diagnostic for prostate cancer that achieves over 90% confidence in accurately detecting PCa gene markers in blood samples. Like our NETest, this biomarker assay plays a crucial role in characterizing the molecular pathology of prostate cancer for treatment guidance and monitoring.

To be made aware when the PROSTest is available to the public, please click the link below to receive notification.

Benefits and Differentiators 

Far Less Invasive: Unlike a biopsy, which relies on harvested prostate tissue, our diagnostic is based on a drop of blood.

Highly accurate: Exhibiting superior performance compared to PSA, our diagnostic demonstrates over 95% accuracy in distinguishing prostate cancer from benign prostatic hyperplasia.

Greater confidence: PROSTest provides diagnostic information necessary for greater confidence in commencing both initial and follow-up treatment

Peer-Reviewed Articles

The Latest News about our Molecular Diagnostics

Our laboratory, methodology, and tests have garnered substantial research, peer-reviewed papers, and media attention. The latest news coverage features the PPQ, a companion to our NETest for PRRT treatment, highlighted in the March issue of the Journal of Nuclear Medicine. This article highlights the efficacy of PPQ in predicting the suitability of PRRT for treating NET patients.